New insights into the regulation of angiotensin receptors

Current Opinion in Nephrology and Hypertension

Volumn 18, Issue 2, 2009, Pages 138-143

  Mogi, Masaki ^a   Iwai, Masaru ^a   Horiuchi, Masatsugu ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Agonistic antibody; Angiotensin receptor; Dimerization; Interacting protein; Ligand independent activation

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR;

ARTICLE; CARBOXY TERMINAL SEQUENCE; DIMERIZATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN FUNCTION;

ANIMALS; CARRIER PROTEINS; DIMERIZATION; GTPASE-ACTIVATING PROTEINS; HUMANS; PHOSPHORYLATION; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ANGIOTENSIN; TUMOR SUPPRESSOR PROTEINS;

EID: 63849254162     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e328324f5fa     Document Type: Article

References (62)

1. de Gasparo M, Catt KJ, Inagami T, et al. International Union of Pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000; 52:415-472.
2. Shivakumar BR, Wang Z, Hammond TG, et al. EP24.15 interacts with the angiotensin II type I receptor and bradykinin B2 receptor. Cell Biochem Funct 2005; 23:195-204.
3. Seachrist JL, Laporte SA, Dale LB, et al. Rab5 association with the angiotensin II type 1A receptor promotes Rab5 GTP binding and vesicular fusion. J Biol Chem 2002; 277:679-685.
4. Scott MG, Pierotti V, Storez H, et al. Cooperative regulation of extracellular signal-regulated kinase activation and cell shape change by filamin A and beta-arrestins. Mol Cell Biol 2006; 26:3432-3445.
5. Pulakat L, Gray A, Johnson J, et al. Role of C-terminal cytoplasmic domain of the AT2 receptor in ligand binding and signaling. FEBS Lett 2002; 524:73- 78.
6. Pulakat L, Cooper S, Knowle D, et al. Ligand-dependent complex formation between the angiotensin II receptor subtype AT2 and Na+/H+ exchanger NHE6 in mammalian cells. Peptides 2005; 26:863-873.
7. Fessart D, Simaan M, Laporte SA. c-Src regulates clathrin adapter protein 2 interaction with beta-arrestin and the angiotensin II type 1 receptor during clathrin-mediated internalization. Mol Endocrinol 2005; 19:491-503.
8. Daviet L, Lehtonen JY, Tamura K, et al. Cloning and characterization of ATRAP, a novel protein that interacts with the angiotensin II type 1 receptor. J Biol Chem 1999; 274:17058-17062.
9. Nouet S, Amzallag N, Li JM, et al. Trans-inactivation of receptor tyrosine kinases by novel angiotensin II AT2 receptor-interacting protein, ATIP. J Biol Chem 2004; 279:28989-28997.
10. Lopez-llasaca M, Liu X, Tamura K, et al. The angiotensin II type I receptor- associated protein, ATRAP, is a transmembrane protein and a modulator of angiotensin II signaling. Mol Biol Cell 2003; 14:5038-5050.
11. Cui T, Nakagami H, Iwai M, et al. ATRAP, novel AT1 receptor associated protein, enhances internalization of AT1 receptor and inhibits vascular smooth muscle cell growth. Biochem Biophys Res Commun 2000; 279:938-941.
12. Hunyady L, Bor M, Balla T, et al. Identification of a cytoplasmic Ser-Thr-Leu motif that determines agonist-induced internalization of the AT1 angiotensin receptor. J Biol Chem 1994; 269:31378-31382.
13. Thomas WG, Motel TJ, Kule CE, et al. Phosphorylation of the angiotensin II (AT1A) receptor carboxyl terminus: a role in receptor endocytosis. Mol Endocrinol 1998; 12:1513-1524.
14. ishizaka N, Griendling KK, Lassegue B, et al. Angiotensin II type 1 receptor: relationship with caveolae and caveolin after initial agonist stimulation. Hypertension 1998; 32:459-466.
15. Gaborik Z, Szaszak M, Szidonya L, et al. Beta-arrestin- and dynamin-dependent endocytosis of the AT1 angiotensin receptor. Mol Pharmacol 2001; 59:239-247.
16. Oshita A, Iwai M, Chen R, et al. Attenuation of inflammatory vascular remodeling by angiotensin II type 1 receptor-associated protein. Hypertension 2006; 48:671-676.
17. Tsurumi Y, Tamura K, Tanaka Y, et al. Interacting molecule of AT1 receptor, ATRAP, is colocalized with AT1 receptor in the mouse renal tubules. Kidney Int 2006; 69:488-494.
18. Tanaka Y, Tamura K, Koide Y, et al. The novel angiotensin II type 1 receptor (AT1 R)-associated protein ATRAP downregulates AT1R and ameliorates cardiomyocyte hypertrophy. FEBS Lett 2005; 579:1579-1586.
19. Guo S, Lopez-llasaca M, Dzau VJ. Identification of calcium-modulating cyclo- philin ligand (CAML) as transducer of angiotensin ll-mediated nuclear factor of activated T cells (NFAT) activation. J Biol Chem 2005; 280:12536-12541.
20. Molkentin JD, Lu JR, Antos CL, et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998; 93:215-228.
21. Guo DF, Sun YL, Hamet P, et al. The angiotensin II type 1 receptor and receptor-associated proteins. Cell Res 2001; 11:165-180.
22. Guo DF, Chenier I, Tardif V, et al. Type 1 angiotensin II receptor-associated protein ARAP1 binds and recycles the receptor to the plasma membrane. Biochem Biophys Res Commun 2003; 310:1254-1265.
23. Guo DF, Chenier I, Lavoie JL, et al. Development of hypertension and kidney hypertrophy in transgenic mice overexpressing ARAP1 gene in the kidney. Hypertension 2006; 48:453-459.
24. Smith RD, Hunyady L, Olivares-Reyes JA, et al. Agonist-induced phosphorylation of the angiotensin AT1 a receptor is localized to a serine/threonine-rich region of its cytoplasmic tail. Mol Pharmacol 1998; 54:935-941.
25. Venema RC, Ju H, Venema VJ, et al. Angiotensin ll-induced association of phospholipase Cgamma 1 with the G-protein-coupled AT1 receptor. J Biol Chem 1998; 273:7703-7708.
26. Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 2007; 292:C82-C97.
27. Seta K, Sadoshima J. Phosphorylation of tyrosine 319 of the angiotensin II type 1 receptor mediates angiotensin ll-induced trans-activation of the epidermal growth factor receptor. J Biol Chem 2003; 278:9019-9026.
28. Zhai P, Galeotti J, Liu J, et al. An angiotensin II type 1 receptor mutant lacking epidermal growth factor receptor transactivation does not induce angiotensin ll-mediated cardiac hypertrophy. Circ Res 2006; 99:528-536.
29. Olivares-Reyes JA, Shah BH, Hernandez-Aranda J, et al. Agonist-induced interactions between angiotensin AT1 and epidermal growth factor receptors. Mol Pharmacol 2005; 68:356-364.
30. Reudelhuber TL The continuing saga of the AT2 receptor: a case of the good, the bad, and the innocuous. Hypertension 2005; 46:1261-1262.
31. Seibold S, Rudroff C, Weber M, et al. Identification of a new tumor suppressor gene located at chromosome 8p21.3-22. FASEB J 2003; 17: 1180-1182.
32. Li JM, Mogi M, Tsukuda K, et al. Angiotensin ll-induced neural differentiation via angiotensin II type 2 (AT2) receptor-MMS2 cascade involving interaction between AT2 receptor-interacting protein and Src homology 2 domain- containing protein-tyrosine phosphatase 1. Mol Endocrinol 2007; 21:499-511.
33. Min U, Mogi M, Iwanami J, et al. Angiotensin II type 2 receptor deletion enhances vascular senescence by methyl methanesulfonate sensitive 2 inhibition. Hypertension 2008; 51:1339-1344.
34. Di Benedetto M, Pineau P, Nouet S, et al. Mutation analysis of the 8p22 candidate tumor suppressor gene ATIP/MTUS1 in hepatocellular carcinoma. Mol Cell Endocrinol 2006; 252:207-215.
35. Frank B, Bermejo JL, Hemminki K, et al. Copy number variant in the candidate tumor suppressor gene MTUS1 and familial breast cancer risk. Carcinogenesis 2007; 28:1442-1445.
36. Di Benedetto M, Bieche I, Deshayes F, et al. Structural organization and expression of human MTUS1, a candidate 8p22 tumor suppressor gene encoding a family of angiotensin II AT2 receptor-interacting proteins, ATIP. Gene 2006; 380:127-136.
37. Wruck CJ, Funke-Kaiser H, Pufe T, et al. Regulation of transport of the angiotensin AT2 receptor by a novel membrane-associated Golgi protein. Arterioscler Thromb Vasc Biol 2005; 25:57-64.
38. Hein L, Meinel L, Pratt RE, et al. Intracellular trafficking of angiotensin II and its AT1 and AT2 receptors: evidence for selective sorting of receptor and ligand. Mol Endocrinol 1997; 11:1266-1277.
39. Senbonmatsu T, Saito T, Landon FJ, et al. A novel angiotensin II type 2 receptor signaling pathway: possible role in cardiac hypertrophy. EMBO J 2003; 22:6471-6482.
40. D'Amore A, Black MJ, Thomas WG. The angiotensin II type 2 receptor causes constitutive growth of cardiomyocytes and does not antagonize angiotensin II type 1 receptor-mediated hypertrophy. Hypertension 2005; 46:1347-1354.
41. Prinster SC, Hague C, Hall RA. Heterodimerization of G protein-coupled receptors: specificity and functional significance. Pharmacol Rev 2005; 57:289-298.
42. AbdAlla S, Lother H, Langer A, et al. Factor XIIIA transglutaminase crosslinks AT1 receptor dimers of monocytes at the onset of atherosclerosis. Cell 2004; 119:343-354.
43. Miura S, Karnik SS, Saku K. Constitutively active homo-oligomeric angiotensin II type 2 receptor induces cell signaling independent of receptor conformation and ligand stimulation. J Biol Chem 2005; 280:18237-18244.
44. AbdAlla S, Lother H, Abdel-tawab AM, et al. The angiotensin IIAT2 receptor is an AT1 receptor antagonist. J Biol Chem 2001; 276:39721-39726.
45. AbdAlla S, Lother H, Quitterer U. AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration. Nature 2000; 407:94-98.
46. AbdAlla S, Lother H, el Massiery A, et al. Increased AT(1) receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness. Nat Med 2001; 7:1003-1009.
47. Abadir PM, Periasamy A, Carey RM, et al. Angiotensin II type 2 receptor- bradykinin B2 receptor functional heterodimerization. Hypertension 2006; 48:316-322.
48. Zeng C, Asico LD, Wang X, et al. Angiotensin II regulation of AT1 and D3 dopamine receptors in renal proximal tubule cells of SHR. Hypertension 2003; 41:724-729.
49. Zeng C, Liu Y, Wang Z, et al. Activation of D3 dopamine receptor decreases angiotensin II type 1 receptor expression in rat renal proximal tubule cells. Circ Res 2006; 99:494-500.
50. Zeng C, Luo Y, Asico LD, et al. Perturbation of D1 dopamine and AT1 receptor interaction in spontaneously hypertensive rats. Hypertension 2003; 42:787-792.
51. Zeng C, Yang Z, Wang Z, et al. Interaction of angiotensin II type 1 and D5 dopamine receptors in renal proximal tubule cells. Hypertension 2005; 45:804-810.
52. Zeng C, Wang Z, Asico LD, et al. Aberrant ETB receptor regulation of AT receptors in immortalized renal proximal tubule cells of spontaneously hypertensive rats. Kidney Int 2005; 68:623-631.
53. Von Bohlen und Halbach O, Walther T, Bader M, et al. Interaction between Mas and the angiotensin AT1 receptor in the amygdala. J Neurophysiol 2000; 83:2012-2021.
54. Bond RA, Ijzerman AP. Recent developments in constitutive receptor activity and inverse agonism, and their potential for GPCR drug discovery. Trends Pharmacol Sci 2006; 27:92-96.
55. Zou Y, Akazawa H, Qin Y, et al. Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nat Cell Biol 2004; 6:499-506.
56. Miura S, Karnik SS. Constitutive activation of angiotensin II type 1 receptor alters the orientation of transmembrane Helix-2. J Biol Chem 2002; 277:24299-24305.
57. Hayashida W, Horiuchi M, Dzau VJ. Intracellular third loop domain of angiotensin II type-2 receptor. Role in mediating signal transduction and cellular function. J Biol Chem 1996; 271:21985-21992.
58. Wallukat G, Homuth V, Fischer T, et al. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest 1999; 103:945-952.
59. Dragun D, Brasen JH, Schonemann C, et al. Patients with steroid refractory acute vascular rejection develop agonistic antibodies targeting angiotensin II type 1 receptor. Transplant Proc 2003; 35:2104-2105.
60. Dragun D, Muller DN, Brasen JH, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005; 352:558-569.
61. Dechend R, Homuth V, Wallukat G, et al. AT1 receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor. Circulation 2000; 101:2382-2387.
62. Dechend R, Homuth V, Wallukat G, et al. Agonistic antibodies directed at the angiotensin II, AT1 receptor in preeclampsia. J Soc Gynecol Invest 2006; 13:79-86.